These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Cardiac aldosterone production in genetically hypertensive rats. Takeda Y; Yoneda T; Demura M; Miyamori I; Mabuchi H Hypertension; 2000 Oct; 36(4):495-500. PubMed ID: 11040225 [TBL] [Abstract][Full Text] [Related]
26. Relationship of Genetic Polymorphisms of Aldosterone Synthase Gene Cytochrome P450 11B2 and Mineralocorticoid Receptors with Coronary Artery Disease in Taiwan. Chou CH; Ueng KC; Yang SF; Wu CH; Wang PH Int J Med Sci; 2016; 13(2):117-23. PubMed ID: 26941570 [TBL] [Abstract][Full Text] [Related]
27. The antagonism of aldosterone receptor prevents the development of hypertensive heart failure induced by chronic inhibition of nitric oxide synthesis in rats. Tsukamoto O; Minamino T; Sanada S; Okada K; Hirata A; Fujita M; Shintani Y; Yulin L; Asano Y; Takashima S; Yamasaki S; Tomoike H; Hori M; Kitakaze M Cardiovasc Drugs Ther; 2006 Apr; 20(2):93-102. PubMed ID: 16761190 [TBL] [Abstract][Full Text] [Related]
28. A patent review of aldosterone synthase inhibitors (2014-present). Wu J; Ding X; Tan X Expert Opin Ther Pat; 2022 Jan; 32(1):13-28. PubMed ID: 34365871 [TBL] [Abstract][Full Text] [Related]
29. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats. Taira M; Toba H; Murakami M; Iga I; Serizawa R; Murata S; Kobara M; Nakata T Eur J Pharmacol; 2008 Jul; 589(1-3):264-71. PubMed ID: 18582458 [TBL] [Abstract][Full Text] [Related]
30. Aldosterone Synthase in Peripheral Sensory Neurons Contributes to Mechanical Hypersensitivity during Local Inflammation in Rats. Mohamed DM; Shaqura M; Li X; Shakibaei M; Beyer A; Treskatsch S; Schäfer M; Mousa SA Anesthesiology; 2020 Apr; 132(4):867-880. PubMed ID: 32011337 [TBL] [Abstract][Full Text] [Related]
31. Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone. Hu X; Li S; McMahon EG; Lala DS; Rudolph AE Mini Rev Med Chem; 2005 Aug; 5(8):709-18. PubMed ID: 16101407 [TBL] [Abstract][Full Text] [Related]
32. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure. Moore TD; Nawarskas JJ; Anderson JR Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934 [TBL] [Abstract][Full Text] [Related]
33. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone. Lainscak M; Pelliccia F; Rosano G; Vitale C; Schiariti M; Greco C; Speziale G; Gaudio C Int J Cardiol; 2015 Dec; 200():25-9. PubMed ID: 26404748 [TBL] [Abstract][Full Text] [Related]
34. Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Delyani JA Kidney Int; 2000 Apr; 57(4):1408-11. PubMed ID: 10760075 [TBL] [Abstract][Full Text] [Related]
35. Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Lea WB; Kwak ES; Luther JM; Fowler SM; Wang Z; Ma J; Fogo AB; Brown NJ Kidney Int; 2009 May; 75(9):936-44. PubMed ID: 19225557 [TBL] [Abstract][Full Text] [Related]
36. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist. Arai K; Homma T; Morikawa Y; Ubukata N; Tsuruoka H; Aoki K; Ishikawa H; Mizuno M; Sada T Eur J Pharmacol; 2015 Aug; 761():226-34. PubMed ID: 26073023 [TBL] [Abstract][Full Text] [Related]
37. Beneficial effects of proanthocyanidins in the cardiac alterations induced by aldosterone in rat heart through mineralocorticoid receptor blockade. Martín-Fernández B; de las Heras N; Valero-Muñoz M; Ballesteros S; Yao YZ; Stanton PG; Fuller PJ; Lahera V PLoS One; 2014; 9(10):e111104. PubMed ID: 25353961 [TBL] [Abstract][Full Text] [Related]